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Background: There is extensive evidence for the role of aberrant cell survival signaling mechanisms in cancer
progression and metastasis. Akt is a major component of cell survival-signaling mechanisms in several types of cancer.
It has been shown that activated Akt stabilizes XIAP by S87 phosphorylation leading to survivin/XIAP complex
formation, caspase inhibition and cytoprotection of cancer cells. We have reported that TGFβ/PKA/PP2A-mediated
tumor suppressor signaling regulates Akt phosphorylation in association with the dissociation of survivin/XIAP
complexes leading to inhibition of stress-dependent induction of cell survival.
Methods: IGF1R-dependent colon cancer cells (GEO and CBS) were used for the study. Effects on cell
proliferation and cell death were determined in the presence of MK-2206. Xenograft studies were performed to
determine the effect of MK-2206 on tumor volume. The effect on various cell death markers such as XIAP, survivin,
AIF, Ezrin, pEzrin was determined by western blot analysis. Graph pad 5.0 was used for statistical analysis. P < 0.05
was considered significant.
Results: We characterized the mechanisms by which a novel Akt kinase inhibitor MK-2206 induced cell death in
IGF1R-dependent colorectal cancer (CRC) cells with upregulated PI3K/Akt signaling in response to IGF1R activation.
MK-2206 treatment generated a significant reduction in tumor growth in vivo and promoted cell death through two
mechanisms. This is the first report demonstrating that Akt inactivation by MK-2206 leads to induction of and
mitochondria-to-nuclear localization of the Apoptosis Inducing Factor (AIF), which is involved in caspase-independent
cell death. We also observed that exposure to MK-2206 dephosphorylated Ezrin at the T567 site leading to the
disruption of Akt-pEzrin-XIAP cell survival signaling. Ezrin phosphorylation at this site has been associated with
malignant progression in solid tumors.
Conclusion: The identification of these 2 novel mechanisms leading to induction of cell death indicates MK-2206
might be a potential clinical candidate for therapeutic targeting of the subset of IGF1R-dependent cancers in CRC.
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The interplay between oncogenic signal transduction
pathways and their downstream mediators has been ex-
tensively characterized over the past two decades. These
signaling events are transmitted by protein-protein inter-
actions that are frequently regulated by phosphorylation
events [1]. PI3K/Akt signaling is a major signal trans-
duction cascade involved in the regulation of a number
of cellular processes including cellular proliferation, sur-
vival, and metabolism. PI3K/Akt signaling has been
implicated in the progression and metastasis of a wide
range of cancers [2]. The Akt protein kinase, comprised
of 3 isoforms (Akt1, 2 and 3), is a direct downstream ef-
fector of PI3K, which becomes fully activated by phos-
phorylation at the T308 and S473 sites [2,3]. Activated
Akt is frequently observed in poorly differentiated tumors
where it bridges the link between various oncogenic re-
ceptors and pro survival cellular functions making the
tumor cells highly invasive and less responsive to chemo-
therapeutic drugs [2,4].
The Akt effects on aberrant cell survival are mediated
by the regulation of a number of critical downstream
proteins that have been implicated in apoptosis and
anoikis including Bad, Caspase9, IKK, Mdm2 and FHKR
[1,5,6]. Akt is also involved in cell cycle regulation by
phosphorylation and inactivation of the cyclin dependent
kinase inhibitors p21 and p27/kip1 [1,7]. Constitutively ac-
tivated Akt has been linked to epithelial-to-mesenchymal
transition (EMT) by regulating MMPs resulting in re-
duced cell-to-cell adhesion, increased motility and inva-
sion. It has also been reported that Akt–driven EMT may
confer the motility required for malignant progression
and dissemination of cancer cells to distant organs [8,9].
Recently, we identified a new pathway by which TGFβ/
PKA/PP2A signaling deactivates Akt phosphorylation
leading to downregulation of IAPs, XIAP and survivin in
colorectal cancer (CRC) cells [10,11].
The broad roles of this enzyme in cancer have estab-
lished Akt as an attractive therapeutic candidate in cancer.
Small molecule inhibitors of the PI3K/Akt pathway are be-
ing developed for clinical use. Several Akt inhibitors have
been synthesized, including MK-2206, a novel allosteric
kinase inhibitor of Akt [12-14]. MK-2206 binds to the
pleckstrin-homology (PH) domain of Akt and thereby in-
hibits PDK1 binding and activation of Akt. This results in
change in confirmation of Akt and its inability to localize
to the plasma membrane [12-14]. MK-2206 has shown
promising preclinical activity and is currently undergoing
phase II clinical evaluation. Although the specific mecha-
nisms underlying the anti-cancer activity of MK-2206
remain to be fully elucidated, MK-2206 has been shown
to induce cell cycle arrest and apoptosis [12-14].
We now report that MK-2206 induces anti-tumor ac-
tivity in a subset of human CRC cell lines characterizedby their dependence on IGF1R signaling which leads to
PI3K/Akt upregulation for cell survival [15]. Strikingly,
exposure to MK-2206 resulted in the generation of 2
mechanisms of cell death, which have not previously been
documented, for this drug. The MK-2206-dependent cell
death of IGF1R-dependent CRC cells in vitro and in vivo
was characterized by Apoptosis Inducing Factor (AIF) in-
duction and its mitochondria-to-nuclear translocation,
which is known to induce caspase-independent cell death
[16,17]. Additionally, MK-2206-dependent cell death was
also characterized by the inactivation of the cytoskeletal
organizing protein Ezrin at T567 leading to the loss of
Inhibitor of Apoptosis (IAP) family protein XIAP. It has
been reported that aberrant increase of Ezrin phosphory-
lation at the T567 site generates increased cell survival
and metastatic capabilities of cancer cells [18-21]. In sum-
mary, our results indicate that MK-2206 is a promising
therapeutic candidate for treatment of IGF1R-dependent
CRC characterized by PI3K/Akt signaling upregulation.
Methods
Cell lines and reagents
GEO [22] and CBS [23] colon carcinoma cells were
cultured in serum free (SF) medium (McCoy’s 5A with
pyruvate, vitamins, amino acids and antibiotics) supple-
mented with 10 ng/ml epidermal growth factor, 20 μg/ml
insulin and 4 μg/ml transferrin at 37°C in a humidified
atmosphere of 5% CO2 [10,11] . When the cells were
under GFDS (growth factor deprivation stress) [24], they
were cultured in Supplemental McCoy’s (SM) medium
in the absence of growth factor or serum supplements
for the indicated times as described previously [24].
HCT 116 (IGF1R- independent colon cancer cell lines)
[25,26] and MiaPaCa (pancreatic cancer cells with con-
stitutive activation of IGF-1R) cells [27] were used as
control to demonstrate the specificity of the dose of the
kinase inhibitor. The in vivo experiments were carried
out with GEO cells stably transfected with a GFP vector
to visualize the tumor size. MK-2206 was provided by
Merck and Co., Inc. MK-2206 was dissolved in DMSO for
in vitro experiments. However, for in vivo experiments
30% Captisol (Cydex Pharmaceuticals) was used as a ve-
hicle for the drug. In in vitro experiments, the control cells
were treated with DMSO. The control animals also re-
ceived 30% Captisol. AIF inhibitor, N- Phenylmaleimide
was purchased from sigma.
Proliferation assay
GEO cells were plated at a density of 8 × 103 cells per well
in a 96 well plate. After 72h the cells were treated with
increasing concentrations of MK-2206. Cell proliferation
was measured after 48h by 3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazoliumbromide (MTT) assay as described
previously [15].
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Cells were seeded in 96 well plates at the same density
as for proliferation assays. MK-2206 was treated 72 h
after plating the CRC cells. DNA fragmentation assays
were performed after 48 h of treatment using a Cell
Death Detection ELISA plus kit (Roche) according to
the manufacturer’s protocol as described previously [24].
To confirm AIF mediated cell death, DNA fragmentation
was performed by pretreating the cells with AIF inhibitor
(50 μM/L) for 1 h prior to treatment with MK-2206 for
48 hrs. Additionally a DNA fragmentation assay was
performed after siRNA-mediated knockdown of AIF
followed by treatment with MK-2206 for 48 hrs. GEO
cells were treated with XIAP siRNA for 48 h and then
DNA fragmentation was performed to confirm the
effect of XIAP on cell death.
Subcellular fractionation
Cells were washed with ice-cold phosphate buffer saline
(PBS) twice. The cells were suspended in 1 ml of PBS
and centrifuged for 1 min at 4°C. The supernatant was
removed, the pellet was dissolved in 1ml of CE buffer,
and samples were vortexed for about 15 sec. The sam-
ples were kept on ice for an hour, passed through a
syringe every 20 minutes and centrifuged for 1 min. The
supernatant was collected and the pellet was left out to
isolate nuclear extract. The supernatant was centrifuged
again for 1 min to get rid of any debris. The supernatant
isolated now was designated as the cytoplasmic extract
and was stored at −80°C. Nuclear extract buffer was
added to the pellet and the sample was vortexed for 20
seconds. The samples were kept on ice for an hour and
sonicated twice for 10 seconds at 60% amplitude. The
samples were centrifuged for 20 min at 4°C and super-
natant collected was stored at −80°C.
Western blot analysis and immunoprecipitation
Cells were lysed in a buffer consisting of 50 mmol/L
Tris–HCl (pH 7.4), 150 mmol/L NaCl, 0.5% NP40, 50
mmol/L NaF, 1 mmol/L NaVO3, 1 mmol/L phenylmethyl-
sulfonyl fluoride, 1 mmol/L DTT, 25 μg/mL aprotinin, 25
μg/mL trypsin inhibitor, and 25 μg/mL leupeptin. The
supernatants were cleared by centrifugation at 4°C. Pro-
tein concentration was measured by bicinchoninic acid
assay (Pierce) using a Biotek 96 well plate reader. Pro-
tein (30–100 μg) was fractionated by electrophoresis on
a 10% acrylamide denaturing gel and transferred onto a
nitrocellulose membrane (Life Science, Amersham) by
electroblotting. The transfer on the nitrocellulose mem-
brane was routinely confirmed by Ponceau S staining.
The membrane was blocked with 5% nonfat dry milk in
TBST [50 mmol/L Tris (pH 7.5), 150 mmol/L NaCl,
0.05% Tween 20] for 1h at room temperature or over-
night at 4°C and washed in TBST. The membrane wasthen incubated with primary antibodies at 1:200–1:1000
in TBST overnight at 4°C. After washing with TBST for
15 min, the membrane was incubated with horseradish
peroxidase–conjugated secondary antibody (Life Science,
Amersham) at 1:1000 dilutions for 1h at room temperature.
The proteins were detected by the enhanced chemilumin-
escence system (Amersham). Immunoprecipitation was
performed with 500 μg of protein samples using magnetic
beads (Millipore) according to manufacturer’s protocol.
Antibodies were purchased from Cell Signaling for tAkt,
pAkt (S473), pAkt(T308), AIF (Apoptosis Inducing Factor),
pEzrin (Thr567), Akt1, Akt2, Akt3 survivin, Bad and pBad
(S136). Ezrin antibody was purchased from Santa Cruz.
XIAP antibody was purchased from Abcam.
Retroviral knockdown of Akt1, Akt2 and Akt3
Small hairpin RNA sequence for Akt1si, Akt2si, Akt3si
and scramblesi were cloned and expressed in a retroviral
expression vector pSUPER.Retro.Puro (Oligoengine). 293T
derived Phi-NX cells were used for transfection. A 19-
nucleotide sequence for Akt1, Akt2 and Akt3 were de-
signed from Dharmacon si design center. The target
sequence for Akt1 5′GAGACTGACACCAGGTATT 3′
was 1634 bases while that for Akt2 5′TGAATGAGGTG
TCTGTCAT 3′ selected was 301 bases downstream of
5′UTR. Akt3 target sequences selected were 5′GCAAA
ATGCCAGTTAATGA 3′. Another non-targeting small
hairpin siRNA was used as an experimental control. The
GEO cells were stably transfected with siRNA to reduce
the expression of Akt1, Akt2 and Akt3. The cells were
selected with Puromycin (4 μg/ml) and the resistant cells
were pooled. Stable cell lines with Akt1, Akt2 and Akt3
knockdown were maintained in serum free medium with
puromycin (4 μg/ml).
RNA interference studies
XIAP siRNA (ON-TARGET plus Human XIAP (331)
siRNA smart pool), AIF si RNA (ON-TARGET plus
Human AIF siRNA smart pool) were purchased from
Thermo scientific and transient transfections were done
as per manufacturer’s protocol.
Immunofluorescence
The translocation of AIF from mitochondria to nucleus
was determined by, immunofluorescence assay. GEO
cells were plated on a cover slip in a six well plate.
When the cells were 60-70% confluent, culture medium
with 400 nm of Mitotracker (CMX Ros, Invitrogen) was
added to the cells. The cells were checked for red fluor-
escence under the microscope after one hour. The cells
were stained, washed with growth medium and fixed by
placing in ice-cold methanol for 5 minutes. The cells
were washed with PBS, permeabilized by incubating with
PBS containing 0.1% Triton X-100 for 15minutes and
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After one hour of blocking, the cells were incubated
with primary antibody for AIF (1:100) for 2 h. Fluores-
cein isothiocyanate- conjugated anti rabbit antibody
(FITC) was used as the secondary antibody. Nuclei were
counter stained with 4′-6 diamino-2- phenylindole and
mounted on glass slide in anti fade vecta shield mount-
ing medium (vector labs). An LSM 510 microscope (Carl
Ziess GmbH, Oberkochen, Germany) was used to per-
form laser confocal microscopy.
Xenograft studies
All the experiments involving animals were approved by
the University of Nebraska Medical Center Institutional
Animal Care and Use Committee. 3–5 week old athymic
nude mice (N = 16) were purchased from NCI. 7×106
GEO GFP labeled cells were subcutaneously injected on
one side in the right flank pad of mice and allowed to
form xenografts. When the tumor size was approxi-
mately 100 mm3, 120 mg/kg body weight of MK-2206 was
administered orally. Captisol was used as a vehicle for
the drug and the control animals were treated with ve-
hicle only. MK-2206 was given orally for 3 weeks on
alternate days. The dose and the duration mentioned in
the study have been provided by Merck and Co. based
on standard mono therapy efficacy studies on mice.
Tumor growth and body weight were measured every
other day. The tumor size was measured manually with
calipers, and the tumor volume was calculated using the
formula (l2 × h × π/6). We used Near-IR enhanced
Macro Imaging System Plus Cooled with the LT-99D2
with the Dual Tool dual excitation upgrade for viewing
the 2D image of the tumor as well as to image the mice.
All in vivo characterizations were confirmed in at least 3
independent control and MK-2206 treated animals.
Terminal deoxynucleotidyl transferase-mediated dUTP
nick end labeling (TUNEL) assay
The mice were euthanized after 21 days of treatment
with MK-2206. The xenograft tumors were harvested
after imaging to determine the size of the tumor using a
microimaging system and immediately placed in 10%
neutral buffered formalin fixative for 24 h. This was
followed by lysate preparation and embedding in paraf-
fin. Sections (4 μM) from paraffin embedded blocks were
stained according to the Apotag terminal nucleotidyl
transferase mediated nick end labeling (TUNEL) assay
kit. The apoptotic rates were determined by counting
the number of positively stained apoptotic bodies at 40×
magnification. Fifteen different fields were randomly se-
lected per slide for analysis. The ratio of the average
number of apoptotic cells to the total number of cells
counted (4000 cells each for control and treated groups)
was used to determine apoptotic rates [28].Hematoxylin and Eosin staining and Ki67 staining
Sections (4 μM) from paraffin embedded blocks were
used for H and E staining and for Ki67 IHC using anti-
body for Ki67 from BD biosciences. Ki67 is a non-
histone nuclear antigen present in late G1, G2 and S
phase of cell cycle but absent in G0. The dilution of Ki67
antibody used was 1:100. The proliferation rate was
determined quantitatively by utilizing NIH Image J soft-
ware (public domain software). Ten different, but histo-
logically similar fields, were selected for analysis [28].
Immunohistochemistry
The slides were deparafinized by keeping them at 60°C
for 1 h and then rehydrated using graded alcohol for 5
min each. Subsequently the slides were treated with
0.3% H2O2/methanol for 10 min and then submerged in
95°C citrate buffer (pH = 7.8) for 15 min. Blocking was
performed in 5% normal goat serum for 1h at room
temperature and then incubated with primary antibody
for tAkt (1:100) and pAkt (1:25) at 4°C overnight. The
slides were treated with Biotinylated secondary antibody
for 30 min at RT, followed by incubation with streptavi-
din peroxidase complex (Invitrogen). Reaction products
were developed using diaminobenzidine containing 0.3%
H2O2 as a substrate for peroxidase (Dako). Nuclei were
counterstained with hematoxylin (Protocol). To deter-
mine the difference in staining intensity for total and
phospho Akt, 10 different but histologically similar fields
were selected per sample and the slides were analyzed
using NIH image J software. The staining intensity mea-
sured by the software was plotted using Graph pad 5.0.
Statistical analysis
Statistical analysis was performed using Graph pad 5.0
software for student’s t test. A P value of less than 0.05
was considered significant.
Results
Effect of MK-2206 on apoptosis of CRC cells
MK-2206 inhibits the phosphorylation of Akt at both
Ser473 and Thr308 in two IGF1R-dependent GEO and
CBS colon cancer cell lines. However the total Akt pro-
tein levels remain unchanged (Figure 1A, B). IGF1R-
independent HCT116 cells [25,26] showed a marginal
loss of pAkt (S473); however MiaPaCa cells with constitu-
tive activation of IGF1R [27] showed a robust loss of pAkt
with MK-2206 treatment (Additional file 1: Figure S1).
We performed MTT assays to study the effect of MK-
2206 on proliferation of IGF1R-dependent colon cancer
cells. MK-2206 treatment for 48 h showed a concentration
dependent reduction in cell proliferation (Figure 2A). The
IC50 value of MK-2206 for GEO cells was observed to be
350 nm. Treatment with 500 nm of MK-2206 reduced cell
proliferation by approximately 75%. DNA fragmentation
Figure 1 MK-2206 inhibits Akt signaling in IGF1R-dependent CRC cells. A) & B) Loss of pAkt at Ser473 and T308 on treatment with increasing
concentration of MK-2206 for 72 hours in GEO and CBS cells respectively. GAPDH is used as a loading control.
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2206 treatment on cell death. It was observed that cell
death increased in a concentration dependent manner on
treatment with MK-2206 as shown in (Figure 2B). Treat-
ment with 500 nm of MK-2206 increased cell death by ap-
proximately 85% as compared to control. Western blot
analysis of various apoptotic markers revealed a decrease
in Bad phosphorylation at Ser136 following treatment
with MK-2206. (Figure 2C). Bad can undergo phosphory-
lation at two sites (Ser112 and Ser136). Akt preferentially
phosphorylates Bad at Ser136 [29]. Phosphorylated Bad
at Ser136 associates with cytoplasmic14-3-3 proteins,.Figure 2 MK-2206 affects cell proliferation and cell death in vitro. A) M
MK-2206. B) DNA fragmentation showing an increase in cell death with inc
apoptotic members as pBad (Ser136), XIAP and Survivin. D) IP for 14-3-3 to det
interaction on treatment with MK-2206. E) IP for Bad to determine the interactTreatment with MK-2206 results in reduced interaction of
pBad with 14-3-3 due to increased cell death (Figure 2D).
On the other hand dephosphorylated Bad interacts with
Bcl-xL a pro-survival molecule, and inactivates it to gener-
ate cell death [29]. We observed that there was an increase
in the interaction of Bcl-xL with total Bad on treatment
with MK-2206 which results in more inactivation of
Bcl-xL thus leading to increased cell death (Figure 2E).
Furthermore, we observed a reduction in the inter-
action of Bad with 14-3-3 on treatment with MK-2206
(Figure 2D). It has been determined previously that
there is an increase in the expression of IAPs (SurvivinTT analysis shows reduction in cell proliferation on treatment with
reasing concentration of MK-2206. C) Western blot analysis of various
ermine the interaction with pBad (Ser136) and Bad showing a loss in the
ion with anti-apoptotic protein Bcl-xL. (* = P < 0.01 and ** = P < 0.001).
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an increase in cell death on transient knockdown of
XIAP as determined by DNA fragmentation, which
confirms that XIAP is responsible for increased survival of
cells by inhibiting caspase-mediated cell death (Additional
file 1: Figure S2). We observed a reduction in the expres-
sion of survivin and XIAP on treatment with MK-2206
in vitro and in vivo (Figure 2C, Additional file 1: Figure S3).
Therefore, MK-2206 regulates aberrant cell survival of
CRC cells by down regulating IAPs in CRC cells.MK-2206 inhibits colon tumor xenograft growth
The antitumor activity of MK-2206 on GEO colon can-
cer xenografts was determined by injection of GEO-GFP
cells subcutaneously into the flank of athymic nude
mice. One week after implanting the cells, MK-2206 was
administered at 120 mg/kg body weight by oral gavage for
three weeks on alternate days. As shown in Figure 3A,
MK-2206 significantly inhibits tumor growth. The tumor
volume was found to be significantly reduced in MK-2206
treated animals (P < 0.01) as compared to control animals
(Figure 3B, C). The excised tumors from control animals
showed an average weight of 2.5 g compared to treated
animal tumors weighing approximately 0.8 g. (Figure 3D).
Importantly, there was no significant decrease in the body
weight in treated animals compared to control (Additional
file 1: Figure S4).
The expression of pAkt S473 was found to be reduced
by treatment with MK-2206 in vivo by IHC (Figure 4A).Figure 3 MK-2206 inhibits the growth of colon tumor xenograft. A) R
tumor volume in treated animals as compared to control animals. C) Redu
compared to control animals. D) Reduction in tumor weight on treatmentDensitometry of the IHC images showed a significant re-
duction in the expression of pAkt S473 in treated ani-
mals as compared to control animals (p < 0.02) as shown
in Figure 4B. The loss of phosphorylation of Akt was
further confirmed by western blot analysis of MK-2206-
treated tumor tissue lysates showing a reduction in pAkt
at both S473 and T308 sites, in comparison to the con-
trol xenograft tumors (Figure 4C). However the change
in total Akt (termed here as tAkt) was not statistically
significant (Additional file 1: Figure S5, Figure S6).MK-2206 inhibits cell proliferation and cell death in vivo
H&E staining indicated that MK-2206 treatment induced
an increase in necrosis that was observed by scanning
the entire tissue section using an image scanner and
visually inspecting the necrotic areas (Additional file 1:
Figure S7). Cell death (quantified by TUNEL assay) was
also observed to be significantly increased following MK-
2206 treatment (Figure 5A, B). MK-2206 treatment also
resulted in reduced cell proliferation as measured by Ki67
staining (Figure 5C, D). Additional file 1: Figure S8
shows the images of control and treated mice prior to
euthanization.Mechanisms of cell death by MK-2206
MK-2206 treatment promotes cell death both in vitro
and in vivo. We characterized the molecular effects
underlying MK-2206 mediated cell death in colon cancer
cells. Western blot analysis showed that there was aneduction in tumor size on treatment with MK-2206. B) Reduction in
ction in the average tumor volume in animals treated with MK-2206 as
with Akt kinase inhibitor. (* = P < 0.01 and ** = P < 0.001).
Figure 4 MK-2206 inhibits Akt signaling in vivo: A) IHC images showing a reduction in pAkt at Ser473. B) Relative quantification was performed,
followed by statistical analysis to determine the decrease in phosphorylation of Akt at Ser473 on treatment with MK-2206. C) Western blot analysis to
confirm the loss of pAkt at Ser473 and Thr 308 in treated animals. (* = P < 0.01 and ** = P < 0.001).
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with MK-2206 (Figure 6A). The mechanism by which
the loss of pAkt might be related to this induction is not
known. Cregan et al. [30] previously reported that AIF is
responsible for caspase-independent apoptosis [30] by
undergoing translocation from the mitochondria to nu-
cleus. To determine the migration of AIF, we prepared
nuclear and cytoplasmic extracts of untreated cells and
cells treated with MK-2206 at 500 nm (since there was a
higher increase in expression of AIF at 500 nm). Immuno-
blot analysis indicated higher AIF expression in nuclear
extracts of cells treated with MK-2206 as compared to
nuclear extracts of untreated cells (Figure 6C), thus
confirming that treatment by MK-2206 stimulates trans-
location of AIF to the nucleus. Translocation of AIF was
further confirmed by immunofluorescence using confocal
microscopy (Figure 6B). AIF mediated cell death was
further confirmed by AIF inhibitor N Phenylmaleimide
[16,17]. Treatment with the AIF inhibitor at a concentra-
tion of 50 μM/L for 1h prior to treatment with MK-2206
for 48 h shows a reduction in cell death thus confirming
MK-2206 mediated cell death is through stimulation of
AIF (Figure 6D). Additionally loss of AIF by siRNA me-
diated knock down results in reduction in cell death in
presence of MK-2206 as determined by DNA fragmen-
tation assay (Additional file 1: Figure S9).In addition to caspase-independent cell death, we
also observed caspase-dependent cell death through
XIAP downregulation following treatment with MK-
2206 (Figure 2D). It has been shown that Akt2 regulates
phosphorylation of Ezrin at T567 leading to the transloca-
tion and activation of the Na+–H+ exchanger (NHE3) [31]
and NHE regulatory factor 1 (NHERF1) supports Akt
dependent cell survival [21]. We observed that MK-2206
might inactivate Ezrin by affecting its phosphorylation at
the T567 site (Figure 7A, B) in vitro as well as in vivo. The
loss of Ezrin phosphorylation is known to affect cellular
survival and proliferation [21]. Stable retroviral knock-
down of Akt2 also results in reduction in Ezrin phos-
phorylation at T567. However there was no change in
expression of total Ezrin on knockdown of Akt2 as
shown in (Figure 7C). Interestingly no such loss of
phospho Ezrin T567 was observed with Akt1 and Akt3
knockdown (Figure 7D, Additional file 1: Figure S10).
Furthermore, Ezrin knock down resulted in complete
loss of XIAP and survivin (Additional file 1: Figure S11).
Therefore, it appears that Akt2 plays an important role in
regulating cell survival mediated by the Akt2-pEzrinT567-
XIAP axis. MK-2206 treatment caused AIF activation and
Ezrin dephosphorylation at the T567 site and, ultimately,
this leads to loss of survivin/XIAP mediated aberrant cell
survival and increased cell death.
Figure 5 Increased cell death and decreased cell proliferation on treatment with the allosteric Akt kinase inhibitor: TUNEL and Ki67 IHC
was performed on control and treated samples A) Increased cell death on treatment with the inhibitor. B) Relative quantification was performed
followed by statistical analysis to quantify the increase in death. There was a significant increase in cell death in treated animals. C) Shows a loss
in cell proliferation on treatment with MK-2206. D) Bar graphs representing a highly significant loss in Ki67 staining in treated animals.
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Extensive drug development efforts and clinical evalua-
tions are underway targeting the aberrant cell survival
properties associated with PI3K/Akt signaling in regulat-
ing cancer progression and metastasis [1]. Inhibition of
Akt activation by small molecule kinase inhibitors is an
attractive candidate for targeting aberrant cell survival
associated with malignant progression and metastasis
and could be effective in the treatment of CRC. MK-
2206 is a novel Akt allosteric kinase inhibitor, which is
currently in clinical evaluation [12-14].
Several studies have described MK-2206 effects as a
single agent or in combination with other inhibitors (e.g.
PI3K or mTOR inhibitors) on cell proliferation and/or
cell death. Gorlick et.al. [32] demonstrated a significant
reduction in tumor volume in vivo and decreased cell
survival in vitro in pediatric cancer cell lines following
MK-2206 treatment. Simoni et.al. [33] studied the effect
of MK-2206 in T cell acute lymphoblastic leukemia dem-
onstrating cell cycle arrest in G0/G1 phase, apoptosis
and autophagy. Ma et.al. [34] showed that MK-2206
treatment in nasopharyngeal carcinoma cells (NPC)
induced cell cycle arrest and apoptosis. Similarly, weobserved that MK-2206 treatment in the IGF1R-
dependent GEO cells reduced cell proliferation and in-
creased cell death in a concentration dependent manner
(Figure 2A, B) while MK-2206 has been shown to be ef-
fective in causing cell death in different types of cancer.
However, specific mechanisms associated with MK-2206-
mediated cell death have not been characterized. This
study identifies molecular mechanisms involved in MK-
2206-mediated cell death in IGF1R- dependent CRC cells
in response to Akt inhibition. Identification of specific
mechanisms may generate new therapeutic targets that
offer potential for enhancing cell death of CRC cells. The
mechanistic novelty of this study is our identification of 2
pathways whereby MK-2206 treatment leads to control of
aberrant cell survival and induction of cell death in vitro
and in vivo.
We studied the expression of various apoptosis-
regulators following exposure to MK-2206. As expected,
a reduction in phospho-Bad (pBad) at the Ser 136 site was
observed (Figure 2D), which is known to be regulated by
Akt signaling [29]. It is known that pBad interacts with
14-3-3, a major mediator of cell survival providing an
anti-apoptotic milieu to the cellular environment [35]. We
Figure 6 Increase in the expression and translocation of AIF on treatment with MK-2206 mediates cell death: A) western blot analysis
showing an increase in the expression of AIF on treatment with MK-2206. Immunofluorescence was performed to study the translocation of AIF
from mitochondria to the nucleus during cell death. B) Confocal images showing a reduced co-localization of mitotracker (red) and AIF (green) in
treated as compared to control cells. C) Cellular fractionation to separate nucleus from cytosol was performed followed by western blot analysis
for AIF. HDAC1 and GAPDH were used as compartmentalization control for nucleus and cytosol respectively. D) DNA fragmentation after treatment
with AIF inhibitor results in reduction in cell death in presence and absence of MK-2206 thus confirming that MK-2206 causes AIF mediated cell death.
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14-3-3 interaction with pBad (Ser136) indicating that MK-
2206 results in reduction in cell survival through this
mechanism. The protein expression of Bad remained un-
changed following MK-2206 treatment; however, there
was an increase in the interaction of Bad with Bcl-xL. Bad
inactivates Bcl-xL thus leading to increases in cell death.
Additionally, we observe a decrease in the interaction of
Bad with 14-3-3 on treatment with MK-2206. This might
suggest that Bad remains activated leading to apoptosis of
colorectal cancer cells.
Strikingly, we made the observation that MK-2206 ex-
posure led to an induction of pro-apoptotic protein AIF
and its translocation from mitochondria to the nucleus
of the GEO cells (Figure 6A, C). It has been reported
that AIF is responsible for caspase-independent death in
ovarian cancer cells [30,36,37]. AIF is localized in the
mitochondria but upon activation it translocates to the
nucleus and causes DNA fragmentation [38]. However,
the mechanism that regulates AIF induction leading to
its caspase-independent apoptotic functions is not well
understood. Treatment with AIF inhibitor resulted inreduced cell death thus indicating that AIF is responsible
for cell death mediated by MK-2206.
MK-2206 treatment of GEO cells reduced survivin and
XIAP levels both in vivo and in vitro (Figure 2D, Additional
file 1: Figure S3). Survivin and XIAP are key cell survival-
associated proteins that have been characterized as having
an important role in metastasis [39]. XIAP binds to cas-
pases 3, 7 and 9 thereby inhibiting their pro-apoptotic
activity [39,40]. During stress conditions, mitochondrial
XIAP and survivin migrate to the cytosol forming a
survivin/XIAP complex, which inhibits caspases and
promotes cytoprotection [40]. Dan et al. [41] made the
novel finding that Akt phosphorylates XIAP at a stabili-
zing Ser87 site. We demonstrated that TGFβ/PKA signa-
ling regulates aberrant cell survival in IGF1R-dependent
CRC cells by disengaging survivin/XIAP complex forma-
tion thus causing caspase activation and inducing cell
death. We sought to determine the mechanism by which
MK-2206 increased XIAP loss and cell death. It was ob-
served that MK-2206 treatment dephosphorylates Ezrin at
the Thr567 site (Figure 7A, B). However, no change in
total Ezrin protein expression was observed. Ezrin is a
Figure 7 Loss of pEzrin on treatment with MK-2206 mediates cell death: A) Western blot analysis showing a reduction in the expression
pEzrin (T567) on treatment with MK-2206 in vitro. B) Treatment with MK-2206 reduces the expression of pEzrin (T567) in vivo. Stable knockdown
of Akt2 was performed in GEO cells. C) Western blot analysis showing a loss of pEzrin (T567) on knockdown of Akt2. No change in total Ezrin was
observed on loss of Akt2. D) Western blot analysis showing loss of Akt1 does not affects the expression of pEzrin (T567). GAPDH is used as a loading
control. E) Overall mechanism for induction of cell death by MK-2206. Akt kinase inhibitor MK-2206 mediates cell death by two different mechanisms.
Loss of phosphorylation of Akt results in induction and translocation of AIF from the mitochondria to the nucleus, where it results in DNA
fragmentation. On the other hand treatment with MK-2206 results in loss of pEzrin (T567), which results in loss of XIAP thus mediating cell death.
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that plays a key role in cancer progression and metastasis
in a wide range of cancers, including CRC [42]. Ezrin is
found in a closed confirmation in the cytosol. Ezrin phos-
phorylation at Thr567 leads to its activation and confor-
mational change to an open conformation resulting in its
localization to the plasma membrane for its oncogenic-
associated functions [43]. Several kinases are known to
phosphorylate Ezrin at T567 including Rho kinase and
PI3K/Akt [44]. We performed siRNA knockdown of
Ezrin and observed a complete loss of XIAP and survivin
(Additional file 1: Figure S11). Thus, we have found that
MK-2206 treatment inhibits the Akt-pEzrinT567-XIAP cell
survival-signaling axis leading to a caspase-dependent cell
death in the IGF1R-dependent CRC cells, in addition to
caspase independent cell death accompanying AIF
translocation from the mitochondria to the nucleus.
Stable knockdown of Akt2 in the IGF1R-dependent
and highly metastatic colon cancer cell line GEO was
performed to give a better understanding of the mechan-
ism of cell death mediated by loss of pEzrin. Loss of
Akt2 resulted in decreased the activation of Ezrin since
there was a loss of phosphorylation of Ezrin at the T567
site. Besides loss of pEzrin we also observed a reduction
in the expression of XIAP on knockdown of Akt2. How-
ever, there was no such loss of pEzrin on knockdown of
Akt1 and Akt3 in GEO cells. Thus we can conclude thatloss of the Akt2 isoform is responsible for Akt-pEzrin-
XIAP mediated cell death.Conclusion
We provided novel mechanistic insights on MK-2206-
mediated cell death. Importantly, this work provides a new
paradigm for MK-2206-mediated control of aberrant cell
survival associated with IGF1R-dependent CRC that may
offer new targets for enhancing cell death in cancer cells.Additional file
Additional file 1: Figure S1. Western blot analysis showing a loss of
pAkt (S473) after treatment with MK-2206 in HCT116 and MiaPaCa cells.
Figure S2. Transfection with siRNA for XIAP results in increase in cell
death as determined by DNA fragmentation. Figure S3. Western blot
analysis to determine the loss of survivin and XIAP in animals treated
with MK-2206. Figure S4. There was no significant loss of body weight in
mice on treatment with MK-2206. Figure S5. IHC images showing no
change in the expression of total Akt in treated animals as compared to
control. Figure S6. Relative quantification followed by statistical analysis
was performed to determine the change in expression of total Akt. There
was no significant change in the expression of total Akt. Figure S7. Eosin
and Hematoxylin staining of control and treated xenograft tumors.
Figure S8. Images of control and treated animals before euthanizing.
Figure S9. A) Western blot showing a knockdown of AIF in presence
of siRNA. B) DNA fragmentation after knockdown of AIF shows reduction in
cell death in presence and absence of MK-2206. Figure S10. No change in
pEzrin (T567) and total Ezrin on knockdown of Akt3. Figure S11. siRNA-
mediated knockdown of Ezrin showing a loss in XIAP expression.
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